Trial · NCT01843205

Buspirone as a Candidate Medication for Methamphetamine Abuse

NCT01843205, Phase 1, Completed, University of Kentucky; results first posted 2018-02-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Buspirone as a Candidate Medication for Methamphetamine Abuse. Trials, record NCT01843205. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01843205

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Buspirone as a Candidate Medication for Methamphetamine Abuse
NCT number: NCT01843205
Status: Completed
Phases: Phase 1
Enrollment: 9 participants, actual
Lead sponsor: University of Kentucky
Conditions: Methamphetamine Dependence, Methamphetamine Abuse
Interventions: Methamphetamine, Placebo
First posted: 2013-04-30
Last updated: 2018-02-07
Results first posted: 2018-02-07

Source ClinicalTrials.gov

Registered outcomes27

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Methamphetamine Doses Self-Administered	One test per methamphetamine dose level per intervention for each participant over his/her approximate 25 day inpatient admission	The reinforcing effects of methamphetamine will be determined during placebo and buspirone treatment using a modified progressive ratio procedure in which subjects are offered the opportunity to earn previously sampled doses of methamphetamine. Each ratio completed on the task will earn 1/10th of the sampled dose.
Secondary	Peak Score on Sedative Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects completed 16 items that loaded into the Sedative Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "sedative" items was summed to yield the Sedative Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both bupsirone and placebo conditions.
Secondary	Peak Score on Stimulant Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects completed 16 items that loaded into the Stimulant Subscale of the Adjective Rating Scale. The items were rated 0-4 on a Likert-type scale and the sum for the 16 "stimulant" items was summed to yield the Stimulant Subscale score. The maximum score for this scale was 64, the minimum was 0. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both bupsirone and placebo conditions.
Secondary	Peak Ratings of "Active, Alert, Energetic" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Active, Alert, Energetic" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Any Effect" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Any Effect" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Bad Effects" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Bad Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Euphoric" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Euphoric" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Good Effects" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Good Effects" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "High" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "High" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions.
Secondary	Peak Ratings of "Irregular/Racing Heartbeat" on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	Subjects rated their feelings of "Irregular/Racing Heartbeat" on a Visual Analog Scale. This item was rated from 0 (minimum)-100 (maximum) on a Visual Analog Scale. Higher values represent greater subjective effects on this item. Peak scores were calculated from multiple assessments for each methamphetamine dose under both buspirone and placebo conditions.

1 to 10 of 27Source ClinicalTrials.gov

See all 27 registered outcomes

Outcomes27

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Methamphetamine Doses Self-Administered	One test per methamphetamine dose level per intervention for each participant over his/her approximate 25 day inpatient admission	Number of Methamphetamine Doses	MEAN
SECONDARY	Peak Score on Sedative Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Score on Stimulant Subscale of the Adjective Rating Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Ratings of Active, Alert, Energetic on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Ratings of Any Effect on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Ratings of Bad Effects on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Ratings of Euphoric on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Ratings of Good Effects on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Ratings of High on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN
SECONDARY	Peak Ratings of Irregular/Racing Heartbeat on the Visual Analog Scale	Subjects completed this measure at 15 minute intervals for 2 hours after sampling each methamphetamine dose under both buspirone and placebo maintenance conditions.	units on a scale	MEAN

1 to 10 of 27Source ClinicalTrials.gov

See all 27 outcomes

Results by group162

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Methamphetamine Doses Self-Administered	Placebo	Placebo Methamphetamine	1.25	Standard Error 1.25	Number of Methamphetamine Doses
Number of Methamphetamine Doses Self-Administered	Buspirone	Placebo Methamphetamine	0	Standard Error 0	Number of Methamphetamine Doses
Number of Methamphetamine Doses Self-Administered	Placebo	10 mg Methamphetamine	6.13	Standard Error 1.72	Number of Methamphetamine Doses
Number of Methamphetamine Doses Self-Administered	Buspirone	10 mg Methamphetamine	4	Standard Error 1.78	Number of Methamphetamine Doses
Number of Methamphetamine Doses Self-Administered	Placebo	30 mg Methamphetamine	7.88	Standard Error 1.42	Number of Methamphetamine Doses
Number of Methamphetamine Doses Self-Administered	Buspirone	30 mg Methamphetamine	7.5	Standard Error 1.64	Number of Methamphetamine Doses
Peak Score on Sedative Subscale of the Adjective Rating Scale	Placebo	Placebo Methamphetamine	3.38	Standard Error 1.66	units on a scale
Peak Score on Sedative Subscale of the Adjective Rating Scale	Buspirone	Placebo Methamphetamine	2.75	Standard Error 1.42	units on a scale
Peak Score on Sedative Subscale of the Adjective Rating Scale	Placebo	10 mg Methamphetamine	3.63	Standard Error 1.08	units on a scale
Peak Score on Sedative Subscale of the Adjective Rating Scale	Buspirone	10 mg Methamphetamine	3.75	Standard Error 1.33	units on a scale

1 to 10 of 162Source ClinicalTrials.gov

See all 162 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Treatment (11 Days)	STARTED	Placebo Then Buspirone	5
First Treatment (11 Days)	STARTED	Buspirone Then Placebo	4
First Treatment (11 Days)	COMPLETED	Placebo Then Buspirone	4
First Treatment (11 Days)	COMPLETED	Buspirone Then Placebo	4
First Treatment (11 Days)	NOT COMPLETED	Placebo Then Buspirone	1
First Treatment (11 Days)	NOT COMPLETED	Buspirone Then Placebo	0
Second Treatment (11 Days)	STARTED	Placebo Then Buspirone	4
Second Treatment (11 Days)	STARTED	Buspirone Then Placebo	4
Second Treatment (11 Days)	COMPLETED	Placebo Then Buspirone	4
Second Treatment (11 Days)	COMPLETED	Buspirone Then Placebo	4

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Placebo	8
Total, all-cause mortality	Buspirone	8
Total, other adverse events	Placebo	8
Total, other adverse events	Buspirone	8
Total, serious adverse events	Placebo	8
Total, serious adverse events	Buspirone	8

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21DA035481	Buspirone as a Candidate Medication for Methamphetamine Abuse	RUSH, CRAIG R	UNIVERSITY OF KENTUCKY	NATIONAL INSTITUTE ON DRUG ABUSE	2013 to 2014

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Buspirone vs Placebo: deaths from any cause	Trial comparisons
Buspirone vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01843205

GET https://conductscience.org/api/trials/v1/NCT01843205/registered?page=2

API reference For AI assistants